ASTH (ASTH) Misses Q4 EPS by 25c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Astrana Health, Inc (ASTH) PT Lowered to $49 at BofA Securities
March 3, 2025 1:40 PM ESTBofA Securities analyst Adam ROn lowered the price target on Astrana Health, Inc (NASDAQ: ASTH) to $49.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "ASTH reported somewhat mixed 4Q results. Despite roughly hitting consensus EBITDA estimates, the company missed its... More
